BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,680,104) by the United States Patent Office.

Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Eli Lilly and Company is teaming up with the American Diabetes Association® and Adam Duvall, American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all people living with diabetes.

Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced today the Journal of Clinical Oncology published clinical results from the KRYSTAL-1 study of adagrasib, a potent and selective KRASG12C inhibitor, demonstrating durable IC activity in patients living with KRASG12C-mutated NSCLC with untreated CNS metastases.

Delix Therapeutics today announced the completion of dosing of the first cohort of subjects in its phase I clinical trial of lead candidate, DLX-001, a non-hallucinogenic psychoplastogen.

Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease.

Leal Health (“Leal’’ or “the Company’’) announced today that it has expanded its platform to include FDA-approved cancer treatment decision support, becoming the industry’s first and only tool that offers patients seeking the best treatment options a single point of access to all relevant FDA-approved, standard-of-care treatments and clinical trials.

Osmind, the public benefit corporation helping clinicians and researchers advance life-saving mental health treatment, today announced the results of a new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy (KIT).

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial utilization review of JELMYTO® (mitomycin) for pyelocalyceal solution.

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today that 29 patients have been dosed in MAIA’s Phase 2 clinical trial, THIO-101, evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC).